Therapeutic neuroprotective agents for amyotrophic lateral sclerosis - Wikidata - awgldk - TriplyDB

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

http://www.wikidata.org/entity/Q27015029

about

Emerging novel concept of chaperone therapies for protein misfolding diseases Exploring new pathways of neurodegeneration in ALS: the role of mitochondria quality control Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial Assisting persons with advanced amyotrophic lateral sclerosis in their leisure engagement and communication needs with a basic technology-aided program.The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?Novel autophagy inducers lentztrehaloses A, B and C Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis Oxidative stress and neurodegenerative disorders N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury.RNA-binding proteins associated molecular mechanisms of motor neuron degeneration pathogenesis.Taurine Protects Glutamate Neurotoxicity in Motor Neuron Cells.Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.Lamotrigine Attenuates Proteasome Inhibition-Induced Apoptosis by Suppressing the Activation of the Mitochondrial Pathway and the Caspase-8- and Bid-Dependent Pathways.The antioxidant effects of riluzole on the APRE-19 celll model injury-induced by t-BHP.Screening the expression characteristics of several miRNAs in G93A-SOD1 transgenic mouse: altered expression of miRNA-124 is associated with astrocyte differentiation by targeting Sox2 and Sox9.A basic technology-aided programme for leisure and communication of persons with advanced amyotrophic lateral sclerosis: performance and social rating.Structure-Function Relationship of Transporters in the Glutamate-Glutamine Cycle of the Central Nervous System.

P2860

Q27002907-47BCE0D4-4202-4126-B492-BB442A8ADE9F Q28391199-7F470B69-BCDE-4094-9042-1A1E256571A8 Q28538939-637A3710-4BA5-4E7F-AA7A-011151590AFC Q30379572-692AF762-A9B7-49EB-939D-5E1C16768CBB Q33633778-351A2AEC-074B-4795-8612-16787A96F829 Q35019375-92E34FDC-8246-40D2-8EA7-EA8516093C0C Q36084934-3C1D353E-7F53-4156-8D2A-DE8D055AD85A Q36925891-A1489C6F-6636-4D94-96DD-97DD900807E9 Q37085041-D094DAF0-34AE-44AA-A2A6-E84F11032BE8 Q37421024-00F7149D-1E74-46C2-8E2E-94D7290F3953 Q37594138-2E871B8E-004D-49B0-9C9F-C2D55C04DA6A Q38232795-3B0A7C44-DB79-43BE-BFF8-623C043781AA Q38693926-9435F715-F20E-4A3B-9EA8-DC371E171731 Q38741121-5338ECAA-E7A2-44F2-916E-43053CEF1B2B Q38768222-CE0F9CA0-0227-43F9-BD1F-2E645373C4A8 Q47140150-2605B46B-24F3-4ADB-96B6-377EB90E5AAF Q47727544-C9A5739C-F0C8-4E89-A752-94FC70F87A46 Q47874342-F30EA6B2-C038-4199-9B77-E2C58070C5BC Q55291849-78EBBBF8-850F-4E12-A95D-E68D80D3DD45

P2860

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

http://www.wikidata.org/entity/Q27015029

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@ast

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@en

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@nl

type

label

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@ast

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@en

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@nl

prefLabel

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@ast

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@en

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@nl

P1433

Q27015029-77AF02CC-2436-4801-B677-DA81A669C6F2

P1476

Q27015029-38179156-36A7-433F-9E9B-C02DAE3B4B82

P2093

Q27015029-4F9C1CA2-A2A4-40F1-9076-9215A8D08582

Q27015029-526DE84E-2C2B-463E-AD83-3A294991DC1E

Q27015029-7A7333D4-A35B-4A34-B779-68FF5226A88E

Q27015029-C8267FA5-F43A-488D-B8AD-B8AAF238549F

Q27015029-F34F1F1C-0936-4919-8250-D6DA3333291A

Q27015029-FE34DBE5-C25F-42F8-A4BF-E47F3ABC68BB

P2860

Q27015029-05A8BAD4-52E6-456F-A394-F68EAA42DDBC

Q27015029-064DCDDC-4DAA-4AE7-B767-AC7BEFD32AD9

Q27015029-065406EB-CC19-422F-8399-01336134E603

Q27015029-0781B80F-1C5D-448A-8026-2BB810B665AB

Q27015029-07DBEFED-094C-4098-8670-799FD5C43524

Q27015029-09AB783A-670E-424D-91B9-A1E9456D43F8

Q27015029-09F31EF3-44DA-4008-BADB-50AC811C8F35

Q27015029-0ABFFF50-FA37-45CB-8CD4-BF60684033F7

Q27015029-0B5348C5-315A-4353-9737-1D53EFAFB95F

Q27015029-0BADD934-AA3E-4C55-B78E-3B5502128461

P2888

Q27015029-D4B6BF2F-F300-4D90-90FA-3F873317E2BF

P304

Q27015029-2FFD1F4E-6D20-4BD6-878A-5366D1FA68C4

P31

Q27015029-3BE81C7B-7D30-46C0-844D-BE098FFF0153

P3181

Q27015029-963353A7-4DFE-4A1C-BBF4-991246FA03BA

P356

Q27015029-0B859441-E43B-4493-A938-21EB95FB544A

P407

Q27015029-7E76D08D-FDE3-4EBC-9290-A9BAC65021EA

P433

Q27015029-55544450-E352-4781-804F-8A8EB40EDE03

P478

Q27015029-00667B52-AD7C-4E97-849E-71F60F722606

P577

Q27015029-8B2AC023-D91C-416A-BCB0-66263BEBDA28

P5875

Q27015029-B1E740C6-44D7-441C-92D8-A68EC09B10F4

P6179

Q27015029-DC6394D6-69BD-40D2-AEFD-07CADA8DDAC2

P698

Q27015029-193553C1-C3ED-4D0A-992B-2C33D6CCEE88

P921

Q27015029-15E97951-5CBA-4EE5-83AD-DAD0A179B47B

P932

Q27015029-C21A746F-AB2A-4B37-A388-FDD4E34C51FB

P3181

P356

S00018-013-1415-0

P1433

Cellular and Molecular Life Sciences

P1476

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

@en

P2093

Haining Zhu

http://www.w3.org/2001/XMLSchema#string

Rachna S. Pandya

http://www.w3.org/2001/XMLSchema#string

Robert Bowser

http://www.w3.org/2001/XMLSchema#string

Robert M. Friedlander

http://www.w3.org/2001/XMLSchema#string

Wei Li

http://www.w3.org/2001/XMLSchema#string

Xin Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Can animal models of disease reliably inform human studies?

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)

Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade

Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis

Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia

Discovery of a proneurogenic, neuroprotective chemical

Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

P2888

s00018-013-1415-0

P304

4729-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

130619

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S00018-013-1415-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

249997448

http://www.w3.org/2001/XMLSchema#string

P6179

1026099461

http://www.w3.org/2001/XMLSchema#string

P698

23864030

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

4172456

http://www.w3.org/2001/XMLSchema#string